Collaborative Agreements (Details Textual) (USD $)
|
3 Months Ended | 9 Months Ended | 12 Months Ended | ||||
---|---|---|---|---|---|---|---|
Sep. 30, 2013
|
Sep. 30, 2012
|
Sep. 30, 2013
|
Sep. 30, 2012
|
Dec. 31, 2011
|
Dec. 31, 2010
|
Dec. 31, 2009
|
|
Research Revenue | $ 0 | $ 0 | $ 0 | $ 186,233 | |||
Research and Development Expense, Total | 1,568,969 | 547,821 | 2,657,936 | 1,696,428 | |||
Other Companies [Member] | Collaborative Arrangement [Member]
|
|||||||
Research and Development Expense, Total | 940,139 | 129,012 | 1,478,534 | 707,086 | |||
Abbott Products, Inc. [Member] | Collaborative Arrangement [Member]
|
|||||||
Upfront License Fees Received | 4,000,000 | ||||||
Milestone Payments Received | 3,000,000 | 2,000,000 | |||||
License Fees And Milestones Revenue | 7,523,437 | ||||||
Research Revenue | 0 | 0 | 0 | 186,233 | |||
Agreement Termination Date | Mar. 29, 2012 | ||||||
Description Of Royalty Payment | All obligations under the prior license agreement have been completed except that Lipocine will owe Abbott a perpetual 1.5% royalty on net sales should Lipocine decide to use certain Solvay/Abbott formulations or a perpetual 1% royalty on net sales should Lipocine use data generated during the term of the Solvay/Abbott agreement in any regulatory filings for a product. | ||||||
Maximum royalty payment for the first two calendar years | 1,000,000 | ||||||
Conditional Royalty Reduction Percentage | 50.00% | ||||||
Collaborative Product Development Agreement With Nexgen Pharma, Inc. [Member] | Research and Development Expense [Member]
|
|||||||
Reimbursement Revenue | $ 0 | $ 0 | $ 468,348 | $ 397,852 |